Immunosuppression and post-transplant hyperglycemia

Current Diabetes Reviews

Volumn 11, Issue 3, 2015, Pages 144-154

  Montero, Nuria ^a   Pascual, Julio ^b,c,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Institut Mar d'Investigacions Mediques   (Spain)

Author keywords

Hyperglycemia; Immunosuppression; Review; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; MYCOPHENOLIC ACID; TARGET OF RAPAMYCIN KINASE;

ARTICLE; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; POST TRANSPLANT DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GRAFT REJECTION; METABOLISM; PROCEDURES; TRANSPLANTATION;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; CALCINEURIN INHIBITORS; CYCLOSPORINE; DIABETES MELLITUS; EVEROLIMUS; GRAFT REJECTION; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION;

EID: 84931829546     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150331160846     Document Type: Article

References (62)

1. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006; 69(3): 588-95.
2. Isrania K, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010; 10(2): 338-53.
3. Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant. 2012; 12(4): 820-8.
4. Ye X, Kuo H-T, Sampaio MS, Jiang Y, Reddy P, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation. 2010; 89(12): 1526-32.
5. Valderhaug TG, Hjelmesaeth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation. 2007; 84(9): 1125-30.
6. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). 2010. Annual Data Report. [Internet].
7. Hecking M, Werzowa J, Haidinger M, et al. Novel views on newonset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013; 28(3): 550-66.
8. Sharif A, Hecking M, de Vries a. PJ, et al. Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions. Am J Transplant. 2014; 14(9): 1992-2000.
9. Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013; 36(9): 2763-71.
10. Porrini E, Prieto MJV, Fuentes MLD, Arevalo M, Ruiz ES, Torres A. The Higher Diabetogenic Risk of Tacrolimus Depends on Pre- Existing Insulin Resistance. A Study in Obese and Lean Zucker Rats. 2013; (12): 1665-75.
11. Sharif A, Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol. Nature Publishing Group; 2010; 6(7): 415-23.
12. Kim YG, Ihm C-G, Lee TW, et al. Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation. 2012; 93(9): 900-7.
13. Tavira B, Coto E, Torres A, et al. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Mol Genet Metab. Elsevier Inc.; 2012; 105(3): 525-7.
14. Zelle DM, Agarwal PK, Ramirez JLP, et al. Alcohol consumption, new onset of diabetes after transplantation, and all-cause mortality in renal transplant recipients. Transplantation. 2011; 92(2): 203-9.
15. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant. 2009; 9(9): 2140- 9.
16. Engelhardt BG, Jagasia SM, Crowe JE, et al. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood. 2012; 119(10): 2417-21.
17. Mutinelli-Szymanski P, Caille A, Tranquart F, et al. Renal resistive index as a new independent risk factor for new-onset diabetes mellitus after kidney transplantation. Transpl Int. 2012; 25(4): 464- 70.
18. Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25(6): 2004-10.
19. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32: 539-46.
20. Van Hooff JP, Christiaans MHL, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004; 19(Suppl 6): vi8-vi12.
21. Olefsky JM, Johnson J, Liu F, Jen P, Reaven GM. The effects of acute and chronic dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes. Metab Clin Exp 2014; 24(4): 517-27.
22. Olefsky JM. Effect of Dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest. Dec 1975; 56(6): 1499-1508.
23. Ullrich S, Berchtold S, Ranta F, et al. Serum- and glucocorticoidinducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion.Diabetes 2005; 54(4): 1090-9.
24. Magnusonssli MA, Quinnsii PG, Grannerss DK. Multihormonal regulation of phosphoenolpyruvate carboxykinasechloramphenicol acetyltransferase fusion genes. J Biol Chem 1987; 262(31): 14917-20.
25. Koizumi M, Yada T. Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca2+ responses to glucose in pancreatic beta-cells. J Endocrinol 2008; 197(2): 221-9.
26. Ranta F. Dexamethasone Induces Cell Death in Insulin-Secreting Cells, an Effect Reversed by Exendin-4. Diabetes 2006; 55(5): 1380-90.
27. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients.Cochrane Database Syst Rev 2009, Issue 1. Art. No.: CD005632. DOI: 10.1002/14651858.CD005632.pub2.
28. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012; 27(2): 825-32.
29. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79(7): 807-14.
30. Woodle ES, First MR, Pirsch J, Shihab F, Gaber a O, Van Veldhuisen P. A prospective, randomized, double-blind, placebocontrolled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248(4): 564-77.
31. Pascual J. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant 2011; 16(6): 600-5.
32. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90(4): 343-9.
33. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for newonset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation 2013; 96(8): 726-31.
34. Montero N, Webster AC, Royuela A, Zamora J, Crespo Barrio M, Pascual J. Steroid avoidance or withdrawal for pancreasand pancreas with kidney transplant recipients. Cochrane Database Syst Rev 2014, Issue 9. Art. No.: CD007669. DOI: 10.1002/14651858.CD007669.pub2.
35. Knight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transplant International 2011; 24(12): 1198-207.
36. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14(4): 512-25.
37. Oetjen E, Baun D, Beimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003; 63(6): 1289-95.
38. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR KS. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443(7109): 345-9.
39. Hui H, Khoury N, Zhao X, et al.Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets.Diabetes 2005; 54(2): 424-33.
40. Webster AC, Taylor RRS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppressionfor kidney transplant recipients. Cochrane Database Syst Rev 2005, Issue 4. Art. No.: CD003961. DOI: 10.1002/14651858.CD003961.pub2.
41. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7(6): 1506-14.
42. Silva HT, Yang HC, Meier-Kriesche H-U, et al. Long-term followup of a phase III clinical trial comparing tacrolimus extendedrelease/ MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014; 97(6): 636-41.
43. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Metaanalysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22(11): 2107-18.
44. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS GL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 4: CD005161.
45. Penninga L, Ei P, Ch M, Iversen M, Da S, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev 2013 May 31; 5: CD008817. doi: 10.1002/14651858.CD008817.pub2.
46. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19(7): 1411-8.
47. Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev 2008; 22(1): 73-81.
48. Peev V, Reiser J, Alachkar N. Diabetes mellitus in the transplanted kidney. Front Endocrinol 2014; 5: 141.
49. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us?Transplant Proc 2009; 41(6 Suppl): S31-8.
50. Balcazar N, Sathyamurthy A, Elghazi L, et al. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. J Biol Chem 2009; 284(12): 7832-42.
51. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppressionin kidney transplant recipients. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD004290. DOI: 10.1002/14651858.CD004290.pub2.
52. Tedesco Silva H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standardexposure CsA in renal-transplant recipients. Am J Transplant 2010; 10(6): 1401-13.
53. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11(8): 1633-44.
54. Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-thenephron trial. Liver Transpl 2013; 19(7): 675-89.
55. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 2012; 93(12): 1179-88.
56. Aasebø W, Midtvedt K, Valderhaug TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010; 25(4): 1289-93.
57. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89(1): 1-14.
58. Thierry A, Mourad G, Büchler M, et al. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. Nephrol Dial Transplant 2012; 27(9): 3651-9.
59. Ho ETL, Wong G, Craig JC, Chapman JR. Once-daily extendedrelease versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation 2013; 95(9): 1120-8.
60. Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int 2012; 25(5): 592-602.
61. Flechner SM, Gurkan A, Hartmann A, et al. A randomized, openlabel study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation 2013; 95(10): 1233-41.
62. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88(10): 1194-202.